Key Points
- Travere Therapeutics insider Elizabeth Reed sold 37,500 shares for approximately $2.34 million at an average price of $62.34, reducing her position by 26.24%; the sale was executed under a pre-arranged Rule 10b5-1 plan.
- Travere reported quarterly revenue of $169.58 million, up 48.2% year over year and above analyst expectations, while its adjusted loss of $0.10 per share beat estimates by $0.03.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $68; several firms recently raised targets to between $70 and $78.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 5,375 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $62.33, for a total transaction of $335,023.75. Following the completion of the transaction, the chief accounting officer directly owned 42,353 shares in the company, valued at approximately $2,639,862.49. The trade was a 11.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Travere Therapeutics Stock Up 2.0%
Shares of TVTX stock opened at $64.74 on Friday. Travere Therapeutics, Inc. has a 12 month low of $22.06 and a 12 month high of $68.73. The stock has a market cap of $6.10 billion, a P/E ratio of -140.74 and a beta of 1.05. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. The company has a 50 day simple moving average of $61.63 and a two-hundred day simple moving average of $48.50.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The business had revenue of $169.58 million for the quarter, compared to analysts' expectations of $157.27 million. During the same quarter last year, the company posted $0.13 EPS. The company's revenue was up 48.2% compared to the same quarter last year. On average, research analysts expect that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current year.
Institutional Investors Weigh In On Travere Therapeutics
A number of institutional investors have recently bought and sold shares of TVTX. Jupiter Topco LLC purchased a new position in shares of Travere Therapeutics in the second quarter worth $643,299,000. Bank of America Corp DE purchased a new position in Travere Therapeutics during the second quarter valued at $259,527,000. Fiera Capital Corp purchased a new position in Travere Therapeutics during the fourth quarter valued at $33,398,000. Wellington Management Group LLP increased its holdings in Travere Therapeutics by 50.0% in the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company's stock valued at $87,094,000 after acquiring an additional 510,808 shares during the last quarter. Finally, Perceptive Advisors LLC lifted its stake in Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock worth $163,469,000 after purchasing an additional 483,565 shares in the last quarter.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Weiss Ratings lowered Travere Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 23rd. TD Cowen raised their price objective on Travere Therapeutics from $60.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $62.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Evercore set a $78.00 price objective on Travere Therapeutics in a research note on Monday, August 10th. Finally, Guggenheim increased their target price on shares of Travere Therapeutics from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $68.00.
View Our Latest Stock Report on Travere Therapeutics
More Travere Therapeutics News
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
- Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
- Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company's work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.
Travere's principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
